Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
复制标题
用重组单核细胞增生李斯特氏菌口服免疫可控制猫免疫缺陷病毒阴道攻击后的病毒载量。
DOI:
10.1128/jvi.78.15.8210-8218.2004
复制
发表时间:
2004
影响因子:
5.4
通讯作者:
Dean,GreggA
中科院分区:
文献类型:
--
作者:
Stevens,Rosemary;Howard,KristinaE;Nordone,Sushila;Burkhard,MaryJo;Dean,GreggA
RecombinantListeria monocytogeneshas many attractive characteristics as a vaccine vector against human immunodeficiency virus (HIV). Wild-type and attenuatedListeriastrains expressing HIV Gag have been shown to induce long-lived mucosal and systemic T-cell responses in mice. Using the feline immunodeficiency virus (FIV) model of HIV we evaluated recombinantL. monocytogenesin a challenge system. Five cats were immunized with recombinantL. monocytogenesthat expresses the FIV Gag and delivers an FIV Env-expressing DNA vaccine (LMgag/pND14-Lc-env). Control cats were either sham immunized or immunized with wild-typeL. monocytogenes(LM-wt). At 1 year after vaginal challenge, provirus could not be detected in any of the nine tissues evaluated from cats immunized with the recombinant bacteria but was detected in at least one tissue in 8 of 10 control animals. Virus was isolated from bone marrow of four of five LMgag/pND14-Lc-env-immunized cats by use of a stringent coculture system but required CD8+T-cell depletion, indicating CD8+T-cell suppression of virus replication. Control animals had an inverted CD4:CD8 ratio in mesenteric lymph node and were depleted of both CD4+and CD8+intestinal epithelial T cells, while LMgag/pND14-Lc-env-immunized animals showed no such abnormalities. Vaginal FIV-specific immunoglobulin A was present at high titer in three LMgag/pND14-Lc-env-immunized cats before challenge and in all five at 1 year postchallenge. This study demonstrates that recombinantL. monocytogenesconferred some control of viral load after vaginal challenge with FIV.